A carregar...
A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker
Background: Recently, there has been a growing interest in applying immune checkpoint blockers (ICBs), so far used to treat cancer, to patients with bacterial sepsis. We aimed to develop a method for predicting the personal benefit of potential treatments for sepsis, and to apply it to therapy by me...
Na minha lista:
| Publicado no: | Front Immunol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7959825/ https://ncbi.nlm.nih.gov/pubmed/33732241 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.616881 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|